Rapport sur la prévention des hépatites post-transfusionnelles non-A non-B

Habibi, B.; Smilovici, W.

doi:10.1016/s0338-4535(88)80057-6

Cited by 24 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a multi center survey, where 10,168 unselected blood donors from nine different areas of France were tested, the mean se roprevalence of anti-HBc was 4.6%. This percentage was ranging from 2.5 to 6.2%, depending on the area [14], A seroprevalence of anti-HBc equal to 40% (21/53) was ob served in HIV-seroconverting regular donors from the Na tional Blood Center when 740,211 donations between July 1985 and July 1988 were examined [6]. This means that 95.4% of the donations are anti-HBc-negative, and that 60% of the donations given after HIV seroconversion are anti-HBc negative.…”

mentioning

confidence: 99%

Anti-HBc Testing Can Decrease the Residual Risk of Transfusion-Related HIV Transmission by More Than One Third

Pont¹,

Massari²,

Jullien³

et al. 1990

Vox Sanguinis

View full text Add to dashboard Cite

mentioning

confidence: 99%

Anti-HBc Testing Can Decrease the Residual Risk of Transfusion-Related HIV Transmission by More Than One Third

Pont¹,

Massari²,

Jullien³

et al. 1990

Vox Sanguinis

View full text Add to dashboard Cite

“…Les hépatites post transfusionnelles non A, non B repré sentent plus de 80 % des hépatites post-transfusionnelles ; l'augmenta tion du nombre d'unités transfusées accroît le risque de recevoir une unité contaminée (13, 22). Avant l'utilisa tion des procédés d'inactivation virale par la chaleur, puis par les solvants détergents, les hémophiles ont con tracté une hépatite post-transfusion nene non A, non B dans plus de 70 % des cas en France (31]. La surveillance des polytransfusés actuellement en cours montre une fréquence de survenue inférieure à 1 % .…”

unclassified

Evaluation de la prévention des hépatites non A, non B post-transfusionnelles en France

Degos¹,

Janot²,

Fleurette³

et al. 1991

Med Sci (Paris)

View full text Add to dashboard Cite

show abstract

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

Colin

Vergnon

Jullien³

et al. 1997

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

The current approach to screening for hepatitis C and non-A, non-B, non-C hepatitis in French blood transfusion centers involves a combination of a transaminase assay and tests for antibodies to hepatitis B core antigen (anti-HBc) and antibodies to hepatitis C virus (anti-HCV). A decision-analysis model was used to assess the cost-effectiveness ratio of this approach compared to the former approach, which included only transaminase and anti-HBc screening. Cost data were collected by a questionnaire sent to 26 centers throughout France. The average costs of diagnostic kits, equipment, staff, and administration were calculated. Estimates of prevalence and sensitivity values came from the medical literature. The cost-effectiveness ratio was expressed in French francs per infected donor detected. A sensitivity analysis of the variables in the model was performed to estimate the validity of the cost-effectiveness ratio. For 100,000 donations the incremental cost of the current approach reached FrF 2,566,111 (about US $500,000), with a marginal effectiveness of 180 donations detected. The sensitivity analysis showed the effect of prevalence on the incremental cost-effectiveness ratio. Transfusion centers may change their screening approach in areas of high or low prevalence of hepatitis C in France.

show abstract

Rapport sur la prévention des hépatites post-transfusionnelles non-A non-B

Cited by 24 publications

References 37 publications

Anti-HBc Testing Can Decrease the Residual Risk of Transfusion-Related HIV Transmission by More Than One Third

Anti-HBc Testing Can Decrease the Residual Risk of Transfusion-Related HIV Transmission by More Than One Third

Evaluation de la prévention des hépatites non A, non B post-transfusionnelles en France

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

Contact Info

Product

Resources

About